20 Feb 2018 07:00
Silence Therapeutics Notice of Results
London, 20th February 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended 31st December, 2017 on Tuesday 6th March 2018.
Ali Mortazavi, Chief Executive Officer and David Ellam, Chief Financial Officer, will host a presentation for analysts at 9:00am on the day of the results at the Devonshire Club, 5 Devonshire Square, London EC2M 4YD.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries:
Optimum Strategic Communications Mary Clark/ Eva Haas/Hollie Vile silence@optimumcomms.com
|
Tel: +44 (0) 20 3714 17 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/